- Gastro Health, a leading gastroenterology group, plans to utilize this simplified blood collection method when recommending the inFoods® IBS to their patients
- Biomerica also announced that inFoods® IBS clinical trial data was presented at the DDW conference May 8th.The data showed that the inFoods® IBS treatment diet significantly improved several key IBS symptoms including Abdominal Pain Intensity (API)
- inFoods IBS showed improvement in API similar to, and in some cases better than, current IBS drugs in the market
NEWPORT BEACH, Calif., May 18, 2023 (GLOBE NEWSWIRE) — Biomerica Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, announced a significant advance in the management of irritable bowel syndrome (IBS). The inFoods® IBS diagnostic test has now been validated for use with finger stick (capillary) patient whole blood samples simplifying sample collection and facilitating wider access to the test. With this new finger stick blood collection option, any trained medical professional in the doctor’s office can collect the patient’s blood sample during their office visit and forward the sample to the Lab for processing. This workflow enhancement greatly simplifies the process for healthcare providers to order the inFoods IBS test and is much easier for patients. The InFoods IBS test will continue to be available using blood collected from a patient’s arm (venipuncture) by a trained phlebotomist.